The global isocitrate dehydrogenase (IDH) inhibitors market, valued at USD 1.7 billion in 2022, is poised for explosive growth, projected to reach an astounding USD 39.16 billion by 2033. This remarkable expansion corresponds to a CAGR of 33% during the forecast period from 2023 to 2033. The significant growth trajectory is primarily driven by the increasing incidence of IDH-mutated cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma, conditions that are frequently managed with IDH inhibitors. The market demonstrated a robust CAGR of 18% in the historical period from 2018 to 2022.
IDH inhibitors have emerged as critical therapeutic agents in the treatment of specific cancers characterized by IDH mutations. As awareness of these mutations grows and diagnostic capabilities improve, more patients are being identified and treated with IDH-targeted therapies. The rising demand for effective treatment options for IDH-mutated cancers is propelling investments in research and development, paving the way for innovative therapies that enhance patient outcomes.
The IDH inhibitors market is expected to benefit from ongoing advancements in drug development, including combination therapies and novel formulations. This growth underscores the urgent need for effective cancer treatments and highlights the pivotal role of IDH inhibitors in the evolving landscape of oncology therapeutics.
Isocitrate dehydrogenase (IDH) inhibitors are a class of drugs that target the mutated form of the IDH enzyme found in certain types of cancer cells. These drugs work by blocking the activity of the mutated IDH enzyme, which is involved in the development and progression of cancer.
The IDH inhibitors market refers to the pharmaceutical industry’s production and sale of these drugs. This market has grown significantly in recent years, with the approval of several IDH inhibitors by regulatory agencies such as the FDA and the EMA.
IDH inhibitors are primarily used in the treatment of acute myeloid leukemia (AML) and other types of cancers, such as cholangiocarcinoma and glioma, that have mutations in the IDH gene. The market for IDH inhibitors is expected to continue to grow as more research is conducted on the use of these drugs in the treatment of cancer.
Market Competition
Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.
- Bayer’s lead IDH inhibitor candidate is called BAY 1436032, which is an oral small molecule inhibitor of the mutated IDH1 enzyme. The drug has been shown to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG) and induce differentiation of leukemia cells in preclinical studies.
- Agios has developed enasidenib (AG-221), an oral small molecule inhibitor of the mutated IDH2 enzyme. Enasidenib works by inhibiting the production of the oncometabolite 2-HG and inducing differentiation of leukemia cells. Enasidenib has been approved by the US FDA for the treatment of relapsed or refractory AML with an IDH2 mutation.
Key Companies Profiled
- Bayer
- Agios Pharma
- Daiichi Sankyo
- Ohm Oncology
- Celgene
- Philogen S.p.A.
- Tragara
- Aslan Pharmaceuticals
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
Key Segments Profiled in the Isocitrate Dehydrogenase (IDH) Inhibitors Industry Survey
Type:
- IDH1 Mutant Medullary Malignant Tumor
- IDH2 Mutant Medullary Malignant Tumor
- Peptides
- Small Molecule
- Others
Molecule Types:
- Monoclonal Antibody
- Peptides
- Small Molecules
- Others
Route of Administration:
- Oral
- Parenteral
- Subcutaneous
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube